Literature DB >> 6608422

Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus.

K Sekita, T Doi, E Muso, H Yoshida, K Kanatsu, Y Hamashima.   

Abstract

Using anti-C3d as a solid phase reagent, C3d fixing circulating immune complexes (CIC) were detected in sera from patients with systemic lupus erythematosus (SLE), rheumatoid arthritis, membranous nephropathy and IgA nephropathy. Particularly, sera from SLE showed the highest CIC levels and highest incidence of positivity among these diseases. In the 51 serum samples from 48 patients with SLE we studied, the CIC detected by the anti-C3d assay correlated well (P less than 0.01) with the CIC detected by the solid phase C1q assay, but not with those detected by the conglutinin assay. In addition, the CIC detected by the anti-C3d assay correlated more significantly (P less than 0.001) with disease activity, as well as some clinical parameters (serum anti-dsDNA antibodies, CH50 and C3 levels) than CIC detected by the other two assays of SLE sera. The anti-C3d binding materials were found to be of intermediate (8-19S) and small (7S) sizes in a small number of SLE sera which we analysed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608422      PMCID: PMC1535930     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody.

Authors:  J S Cameron; M H Lessof; C S Ogg; B D Williams; D G Williams
Journal:  Clin Exp Immunol       Date:  1976-09       Impact factor: 4.330

2.  Routine assay for the detection of immune complexes of known immunoglobulin class using solid phase C1q.

Authors:  F C Hay; L J Nineham; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

3.  Solid-phase enzyme immunoassay or radioimmunoassay for the detection of immune complexes based on their recognition by conglutinin: conglutinin-binding test. A comparative study with 125I-labelled Clq binding and Raji-cell RIA tests.

Authors:  P Casali; A Bossus; N A Carpentier; P H Lambert
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

Review 4.  Immune complex disease in experimental animals and man.

Authors:  C G Cochrane; D Koffler
Journal:  Adv Immunol       Date:  1973       Impact factor: 3.543

5.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

6.  Clq: rapid purification method for preparation of monospecific antisera and for biochemical studies.

Authors:  K Yonemasu; R M Stroud
Journal:  J Immunol       Date:  1971-02       Impact factor: 5.422

7.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

8.  Use of bovine conglutinin for the assay of immune complexes.

Authors:  R A Eisenberg; A N Theofilopoulos; F J Dixon
Journal:  J Immunol       Date:  1977-04       Impact factor: 5.422

9.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution.

Authors:  M K Pangburn; R D Schreiber; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

10.  Studies on the mechanism of solubilization of immune precipitates by serum.

Authors:  J Czop; V Nussenzweig
Journal:  J Exp Med       Date:  1976-03-01       Impact factor: 14.307

View more
  4 in total

1.  Comparative studies on immunoglobulins, complement component (C3), albumin, and immunoglobulin A-containing circulating immune complexes in serum and bile of patients with biliary obstruction.

Authors:  G Ohshio; F Furukawa; T Manabe; T Tobe; Y Hamashima
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

2.  Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus.

Authors:  E Röther; B Lang; R Coldewey; K Hartung; H H Peter
Journal:  Clin Rheumatol       Date:  1993-03       Impact factor: 2.980

3.  Rationale for bone marrow transplantation in the treatment of autoimmune diseases.

Authors:  S Ikehara; R A Good; T Nakamura; K Sekita; S Inoue; M M Oo; E Muso; K Ogawa; Y Hamashima
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

4.  Complement Receptor 2 Based Immunoassay Measuring Activation of the Complement System at C3-Level in Plasma Samples From Mice and Humans.

Authors:  Lene Halkjær; Anne Troldborg; Henrik Pedersen; Lisbeth Jensen; Annette Gudmann Hansen; Troels Krarup Hansen; Mette Bjerre; Jakob Appel Østergaard; Steffen Thiel
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.